SCHEMBL9926068

SCHEMBL9926068

Cc1ccc(N2CCN(C(=O)[C@@H]3CN(S(=O)(=O)c4cc(Cl)c(Cl)s4)C[C@H]3c3ccccc3)CC2)cc1C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.45
ALDH1A1 P00352 3/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TSHR P16473 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
SIGMAR1 Q99720 1/20 0.41
AR P10275 2/20 0.40
SMN1; SMN2 Q16637 7/20 0.39
CHRM1 P11229 1/20 0.39
HTT P42858 1/20 0.39
MC4R P32245 1/20 0.37
GFER P55789 1/20 0.37
CYP3A4 P08684 1/20 0.37
GAA P10253 1/20 0.37
ALOX12 P18054 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9926099 0.90 SIGMAR1 (0.51) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL9926065 0.89 MAPT (0.46) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL5268950 0.89 MAPT (0.46) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL9926069 0.88 SMN1; SMN2 (0.50) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL5270813 0.88 AR (0.46) MAPTKMT2AARSMN1; SMN2MC4R
SCHEMBL9925998 0.88 AR (0.46) MAPTKMT2AARSMN1; SMN2MC4R
SCHEMBL5268393 0.88 SMN1; SMN2 (0.50) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL5264662 0.87 MAPT (0.50) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL9926066 0.87 MAPT (0.50) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL9926090 0.86 AR (0.46) ARHTTMC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836180-B1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI SA (FR) 2012-06-13 EP disclosed
US-7468369-B2 Sulfonyl pyrrolidines, method for producing the same and their use as drugs SANOFI-AVENTIS (FR) 2008-12-23 US disclosed
US-7468369-B2 Sulfonyl pyrrolidines, method for producing the same and their use as drugs SANOFI-AVENTIS (FR) 2008-12-23 US disclosed
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-21 US disclosed
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SLC5A1, SLC5A2, KCNJ1 MAPT 4225/4885ALDH1A1 959/4885LMNA 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.